A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials. A vaccine preventing infection and transmission of SARS-CoV-2 is needed. Here, Wu et al. generate an adenovirus-vector vaccine expressing SARS-CoV-2 spike protein and show that a single dose of mucosal vaccination protects mice and ferrets from infection and inhibits virus replication in the upper respiratory tract.

• Publication year

  2020

• Venue

  Nature Communications

• Publication date

  2020-08-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41467-020-17972-1PMID 32796842PMCID 7427994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

  2021cited by this paper
• Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.

  2020cited by this paper
• Development of an inactivated vaccine candidate for SARS-CoV-2

  2020cited by this paper
• DNA vaccine protection against SARS-CoV-2 in rhesus macaques

  2020cited by this paper
• Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

  2020cited by this paper
• ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

  2020cited by this paper
• Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

  2020cited by this paper
• Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

  2020cited by this paper
• Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma.

  2019cited by this paper
• Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models

  2018cited by this paper
• Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.

  2017cited by this paper
• Live attenuated influenza vaccine use and safety in children and adults with asthma.

  2017cited by this paper
• Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2017cited by this paper
• Pediatric Asthma and Viral Infection

  2016cited by this paper
• Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection.

  2016cited by this paper
• Respiratory Virus Vaccines

  2015cited by this paper
• Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.

  2015cited by this paper
• Safety of live attenuated influenza vaccine in atopic children with egg allergy

  2015cited by this paper
• A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

  2012cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice

  2008cited by this paper

• Fasting impairs humoral immunological memory by β-hydroxybutyrate-mediated depletion of plasma cells.

  2026cites this paper
• Airborne transmission-mediated delivery of a live-attenuated influenza virus vector-based intranasal COVID-19 vaccine protects Syrian hamsters against SARS-CoV-2 challenge

  2025cites this paper
• Effects of protein boosters on antibody responses

  2025cites this paper
• Respiratory mucosal vaccines: Applications, delivery strategies and design considerations.

  2025cites this paper
• An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice

  2025cites this paper
• An Aptamer-Based gFET-Sensor for Specific Quantification of Gene Therapeutic Human Adenovirus Type 5

  2025cites this paper
• A viral vector prime and protein boost vaccine regimen elicits higher binding antibody titers than a homologous viral vector prime-boost regimen

  2025cites this paper
• Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate.

  2025cites this paper
• Molecular basis of Ad5-nCoV vaccine-induced immunogenicity.

  2025cites this paper
• Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy

  2025cites this paper
• Immunobiology and immunotherapy of COVID-19.

  2025cites this paper
• Transmission of SARS-CoV-2 between ferrets in presence of pre-existing immunity

  2025cites this paper
• Research advances in replication-deficient viral vector vaccines

  2025cites this paper
• A SARS-CoV-2 mucosal nanovaccine based on assembly of maltodextrin, STING agonist and polyethyleneimine.

  2025cites this paper
• Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used

  2025cites this paper
• Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma

  2025cites this paper
• Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus

  2025cites this paper
• An oral recombinant human type 5 adenovirus vector vaccine encoding the S protein of Type I feline coronavirus effectively protection against FCoV challenge in cats.

  2025cites this paper
• A Recombinant lipidated Receptor-binding domain Is a Promising Self-Adjuvanting Antigen for Mucosal Vaccine

  2025cites this paper
• Advances in adenovirus-based coronavirus vaccines

  2025cites this paper
• IgG binding characteristics of ferret Fcγ receptors

  2025cites this paper
• Dosing and Serostatus Shape the Efficacy of Adenovirus, mRNA, and Protein Vaccines

  2025cites this paper
• Evaluation of the protective efficacy of a recombinant adenovirus-vectored SARS-CoV-2 vaccine candidate for veterinary use

  2025cites this paper
• Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2

  2025cites this paper
• Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.

  2025cites this paper
• A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine

  2024cites this paper
• COVID-19 Vaccines: Where Did We Stand at the End of 2023?

  2024cites this paper
• A chimeric adenovirus‐vectored vaccine based on Beta spike and Delta RBD confers a broad‐spectrum neutralization against Omicron‐included SARS‐CoV‐2 variants

  2024cites this paper
• Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19

  2024cites this paper
• Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris

  2024cites this paper
• Protective efficacy of a recombinant adenovirus expressing novel dual F and HN proteins of bovine parainfluenza virus type 3

  2024cites this paper
• Development of NP-Based Universal Vaccine for Influenza A Viruses

  2024cites this paper
• Rabies virus-based oral and inactivated vaccines protect minks against SARS-CoV-2 infection and transmission1

  2024cites this paper
• Application of multivariate data analysis on historical recombinant adenovirus zoster vaccine production data for upstream process improvements.

  2024cites this paper
• A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines.

  2024cites this paper
• Chicken Secondary Lymphoid Tissues—Structure and Relevance in Immunological Research

  2024cites this paper
• Evaluation of two inoculation routes of an adenovirus-mediated viral protein inhibitor in a Crimean-Congo hemorrhagic fever mouse model

  2024cites this paper
• Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.

  2024cites this paper
• Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

  2024cites this paper
• A Mathematical Model for Controlling SARS-COV 2 by Triplet Oxygen Molecules, Spinning Bubbles and Other Spinors

  2024cites this paper
• Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice

  2024cites this paper
• Beyond COVID-19: the promise of next-generation coronavirus vaccines

  2024cites this paper
• SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review

  2024cites this paper
• SARS-CoV-2 immunity in animal models

  2024cites this paper
• A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov

  2023cites this paper
• Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines

  2023cites this paper
• Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines

  2023cites this paper
• Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

  2023cites this paper
• Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19

  2023cites this paper
• Nanotechnology of inhalable vaccines for enhancing mucosal immunity

  2023cites this paper
• Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity

  2023cites this paper
• Development of Adenovirus-Based Covid-19 Vaccine Candidate in Indonesia

  2023cites this paper
• SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

  2023cites this paper
• A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

  2023cites this paper
• A Newly Identified Spike Protein Targeted Linear B‐Cell Epitope Based Dissolvable Microneedle Array Successfully Eliciting Neutralizing Activities against SARS‐CoV‐2 Wild‐Type Strain in Mice

  2023cites this paper
• Identification of an immunodominant neutralizing epitope of porcine Deltacoronavirus spike protein.

  2023cites this paper
• Inside-out assembly of viral antigens for the enhanced vaccination

  2023cites this paper
• Comparative evaluation of protective immunity against Francisella tularensis induced by subunit or adenovirus-vectored vaccines

  2023cites this paper
• Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein

  2023cites this paper
• Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines

  2023cites this paper
• Biomedical equipments, vaccine and drug in the prevention, diagnosis and treatment of COVID-19

  2023cites this paper
• Assessment of BoHV-4-based vector vaccine intranasally administered in a hamster challenge model of lung disease

  2023cites this paper
• Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity.

  2023cites this paper
• Ferrets: A powerful model of SARS-CoV-2

  2023cites this paper
• Virus-like Magnetic Mesoporous Silica Particles as a Universal Vaccination Platform against Pathogenic Infections.

  2023cites this paper
• Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice

  2023cites this paper
• Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model

  2023cites this paper
• Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine

  2023cites this paper
• Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report

  2023cites this paper
• An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice

  2023cites this paper
• A multiadjuvant polysaccharide-amino acid-lipid (PAL) subunit nanovaccine generates robust systemic and lung-specific mucosal immune responses against SARS-CoV-2 in mice

  2023cites this paper
• Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity

  2023cites this paper
• Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine

  2023cites this paper
• A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants

  2023cites this paper
• Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model

  2023cites this paper
• Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines.

  2023cites this paper
• Challenges and future directions for next-generation biomedical polymersomes

  2023cites this paper
• Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective.

  2023cites this paper
• Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern

  2023cites this paper
• Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19Short tille: Next-generation mucosal COVID-19 vaccines

  2023cites this paper
• Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.

  2023cites this paper
• Comparative Immunogenicity of the Gam-COVID-Vac Vaccine under Intranasal and Intramuscular Administration

  2023cites this paper
• Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine

  2023cites this paper
• BPI23-Fcγ alleviates lethal multidrug-resistant Acinetobacter baumannii infection by enhancing bactericidal activity and orchestrating neutrophil function.

  2023cites this paper
• SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.

  2023cites this paper
• Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination

  2023cites this paper
• Classification of five SARS-CoV-2 serotypes based on RBD antigenicities.

  2023cites this paper
• Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

  2023cites this paper
• Subunit vaccine raised against the SARS‐CoV‐2 spike of Delta and Omicron variants

  2023cites this paper
• Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice

  2023cites this paper
• Heterologous Prime-boost with Chimpanzee Adenovirus Vector and Receptor-Binding Domain Recombinant Subunit Protein COVID-19 Vaccine Induces Strong Immune Responses in Mice

  2023cites this paper
• Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

  2022cites this paper
• Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

  2022cites this paper
• Vaccines Against COVID-19: A Review

  2022cites this paper
• Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

  2022cites this paper
• A novel intranasal administration adenoviral vector-based platform for rapid COVID-19 vaccine development

  2022cites this paper
• Discovery of compounds inhibiting SARS-COV-2 multi-targets

  2022cites this paper
• Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology

  2022cites this paper
• COVID-19: vaccines, efficacy and effects on variants

  2022cites this paper
• Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice

  2022cites this paper